Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991

Mol Cancer Ther. 2002 Jul;1(9):657-65.

Abstract

Epidemiological studies suggest potent anticancer effects of tea catechins. Previously, we have reported (I. Naasani et aL, Biochem. Biophys. Res. Commun., 249: 391-396, 1998) that epigallocatechin gallate (EGCG), a major tea catechin, strongly and directly inhibits telomerase, a ribonucleoprotein that maintains telomeres and has been implicated in tumorigenesis. Here, we describe newly synthesized compounds MST-312, MST-295, and MST-199, as more effective telomerase inhibitors than EGCG. Continuous treatment of human monoblastoid leukemia U937 cells with a nontoxic dose of each drug caused progressive telomere shortening and eventual reduction of growth rate accompanied by induction of the senescence-associated beta-galactosidase activity. Particularly, in the case of MST-312, the effective dose required for the telomere shortening was 1-2 microM, which was 15- to 20-fold lower than that of EGCG. These compounds may provide a novel chemotherapeutic strategy for the treatment of cancers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Apoptosis
  • Benzamides / therapeutic use*
  • Blotting, Southern
  • Catechin / analogs & derivatives*
  • Catechin / therapeutic use*
  • Chromones / therapeutic use*
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / therapeutic use*
  • Humans
  • Models, Chemical
  • Phenotype
  • Telomerase / antagonists & inhibitors
  • Telomere / physiology*
  • Time Factors
  • U937 Cells
  • beta-Galactosidase / metabolism

Substances

  • Antineoplastic Agents
  • Benzamides
  • Chromones
  • Enzyme Inhibitors
  • MST 199
  • MST 295
  • MST 312
  • Catechin
  • epigallocatechin gallate
  • Telomerase
  • beta-Galactosidase